Cue Biopharma names Dominique Borie as CMO insider

Cue Biopharma, Inc. reports Dominique Christian Borie, its Chief Medical Officer and Head of Research & Development, as a reporting person on a Form 3 (initial statement of beneficial ownership of securities).

Rhea-AI Filing Summary

Cue Biopharma, Inc. reports Dominique Christian Borie, its Chief Medical Officer and Head of Research & Development, as a reporting person on a Form 3 (initial statement of beneficial ownership of securities). The Form 3 data shows no reported share transactions or derivative exercises by Borie.

Key Figures

Buy transactions reported: 0 Sell transactions reported: 0 Derivative exercises reported: 0

3 metrics

Buy transactions reported 0 buyCount in the Form 3 transaction summary

Sell transactions reported 0 sellCount in the Form 3 transaction summary

Derivative exercises reported 0 exerciseCount in the Form 3 transaction summary

Key Terms

reporting person, Chief Medical Officer, ten percent owner

3 terms

reporting person regulatory

""reportingPersons": [{ "name": "Borie Dominique Christian""

Chief Medical Officer regulatory

"officer_title": "Chief Medical Officer""

A chief medical officer is a senior executive responsible for overseeing the health and medical strategies within an organization, often in the healthcare or pharmaceutical sectors. They play a key role in guiding decisions related to medical research, product safety, and healthcare policies, which can impact a company's reputation and success. For investors, understanding the chief medical officer's role helps gauge how well a company manages medical risks and advances its healthcare goals.

ten percent owner regulatory

""is_ten_percent_owner": 0"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who is the reporting person in Cue Biopharma (CUE)'s latest Form 3?

The reporting person is Dominique Christian Borie, Cue Biopharma’s Chief Medical Officer and Head of Research & Development. The Form 3 identifies Borie as an officer subject to SEC insider reporting requirements.

What role does Dominique Christian Borie hold at Cue Biopharma (CUE)?

Dominique Christian Borie serves as Chief Medical Officer and Head of Research & Development at Cue Biopharma. This officer status makes Borie a reporting person for SEC ownership disclosures such as Form 3.

Does the Form 3 for Cue Biopharma (CUE) report any share purchases or sales?

No share purchases or sales are reported. The transaction summary shows 0 buy, 0 sell, and 0 derivative exercise transactions, indicating the Form 3 functions purely as an initial ownership statement without trading activity.

What is the purpose of this Form 3 related to Cue Biopharma (CUE)?

Form 3 serves as an initial statement of beneficial ownership for Dominique Christian Borie as an officer of Cue Biopharma. It establishes Borie’s status as an insider subject to ongoing SEC reporting on future transactions.

Is Dominique Christian Borie a ten percent owner of Cue Biopharma (CUE)?

Dominique Christian Borie is not listed as a ten percent owner. The Form 3 flags Borie as an officer, not a director or ten percent owner, clarifying the capacity in which insider reporting obligations apply.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/15/2026 - 06:58 PM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Borie Dominique Christian

(Last) (First) (Middle)

C/O CUE BIOPHARMA, INC.

40 GUEST STREET

(Street)

BOSTON MASSACHUSETTS 02135

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
07/13/2026

3. Issuer Name and Ticker or Trading Symbol
Cue Biopharma, Inc. [ CUE ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)	X	Other (specify below)
	Chief Medical Officer		Head of Research & Development

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Dominique Borie	07/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)